【Abstract】Objective To determine the effectiveness and safety of rHuEPO madein chronic renal failure predialysis patient. Method using random, oneself contrasted method. 46 cases chronic renal failure predialysis patients received rHuEPO subcutaneouly,two times per week. The duration of rHuEPO therapy was 12weeks. Results Remarkable improvement rate of patient was 56.5%(26/46). Significant improvement rate of patient was 39.1%(18/46). No effectiveness rate of patient was 4.3%(2/46). Conclusions In our study, the treatment of chronic renal anemia predialysispatinent with rHuEPO was effectiveness and safety. rHuEPO related side effects was hypertension in 7(15.2%) patient.
PDF(2221 KB)
